Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer | Zendy

Komal Jhaveri | Zendy; Carlos Henrique dos Anjos | Zendy; Tony Taldone | Zendy; Rui Wang | Zendy; Elizabeth Comen | Zendy; Monica Fornier | Zendy; Jacqueline Bromberg | Zendy; Weining Ma | Zendy; Sujata Patil | Zendy; Anna Rodina | Zendy; Nagavarakishore Pillarsetty | Zendy; Susan Duggan | Zendy; Sarhe Khoshi | Zendy; Nathan Kadija | Zendy; Gabriela Chiosis | Zendy; Mark Dunphy | Zendy; Shanu Modi | Zendy

Open Access

Measuring Tumor Epichaperome Expression Using [¹²⁴I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer

Author(s) -

Komal Jhaveri,

Carlos Henrique dos Anjos,

Tony Taldone,

Rui Wang,

Elizabeth Comen,

Monica Fornier,

Jacqueline Bromberg,

Weining Ma,

Sujata Patil,

Anna Rodina,

Nagavarakishore Pillarsetty,

Susan Duggan,

Sarhe Khoshi,

Nathan Kadija,

Gabriela Chiosis,

Mark Dunphy,

Shanu Modi

Publication year - 2020

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.20.00273

Subject(s) - positron emission tomography , breast cancer , paclitaxel , medicine , metastatic breast cancer , nuclear medicine , biomarker , cancer , oncology , chemistry , biochemistry

Epichaperome network maintenance is vital to survival of tumors that express it. PU-H71 is an epichaperome inhibitor that binds to the ATP-binding site of HSP90 and has demonstrated antitumor activity in breast cancer xenograft models and clinical safety in patients. PU-positron emission tomography (PET) is a theragnostic imaging tool that allows visualization of the epichaperome target. In this phase Ib trial, we present safety and tolerability for PU-H71 plus nab-paclitaxel in HER2-negative patients with metastatic breast cancer (MBC) and the utility of PU-PET as a noninvasive predictive biomarker.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research